Themis Medicare Limited · NSE:THEMISMED
Themis Medicare — Q2 & H1 FY24 Earnings Presentation
19 slides from Themis Medicare's earnings presentation, Nov 4, 2023
Slide 1: Exchange filing cover letter
TML: CS: BSE/NSE CORR: 2023-24 4th November, 2023 Listing Department, Listing Department, BSE Limited, National Stock Exchange of India Ltd. P. J. Towers, Dalal Street, “Exchange Plaza”, Mumbai-400001 Bandra – Kurla Complex, BSE Scrip Code: 530199 Bandra – East, Mumbai- 400 051 NSE Scrip Code: THEMI
Slide 2: Themis Medicare Ltd. Investor Presentation Q2 & H1 FY24
In every possibility lies an innate, latent power to change lives Themis Medicare Ltd. Investor Presentation Q2 & H1 FY24
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Themis Medicare Limited (the “Company” or “Themis” or “TML”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in
Slide 4: Table of Contents
Table of Contents Consolidated Financial Highlights Company Overview Way Ahead 3
Slide 5: Consolidated Financial Highlights
Consolidated Financial Highlights
Slide 6: Management Comment
Management Comment Commenting on the result, Dr. Sachin Patel, Managing Director & CEO. said- “The second quarter and half yearly performance is commensurate with our stated strategy of aggressively growing our Hospital Business and am glad to share that this segment has grown by 20% in Q2FY24 on y-
Slide 7: Consolidated Quarterly Financial Highlights
Consolidated Quarterly Financial Highlights Revenue (Rs. Cr.)* EBITDA (Rs. Cr.)** / Margin (%) 25 23.5% 22.5% 25% 104.8 96.7 91.0 88.8 20 17.2% 20% 80.1 21.7 21.3 15 13.1% 11.8% 15% 10 15.3 12.4 10% 10.5 5 5% 0 0% Q2 FY23 Q3 FY23 Q4 FY23 Q1 FY24 Q2 FY24 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 PAT (Rs. Cr
Slide 8: Consolidated Quarterly Financial Highlights – Q2 FY24
Consolidated Quarterly Financial Highlights – Q2 FY24 Particulars (Rs. Cr.) Q2 FY24 Q2 FY23 Y-o-Y (%) Q1 FY24 Net Revenue 104.78 91.00 15.14% 96.65 Cost of Material Consumed 26.18 17.71 15.71 Purchase of SIT 13.92 5.29 9.79 Changes in Inventory 1.84 4.53 3.57 Employee Expenses 19.86 15.48 20.17 Othe
Slide 9: Consolidated Half-yearly Financial Highlights – H1 FY24
Consolidated Half-yearly Financial Highlights – H1 FY24 Particulars (Rs. Cr.) H1 FY24 H1 FY23 Y-o-Y (%) Net Revenue 201.43 185.44 8.62% Cost of Material Consumed 41.89 35.96 Purchase of SIT 23.71 13.27 Changes in Inventory 5.41 7.90 Employee Expenses 40.03 31.80 Other Expenses 56.25 54.80 Total Expe
Slide 10: Consolidated Balance Sheet as on 30th Sep'23
Consolidated Balance Sheet as on 30th Sep’23 As on 30th As on 31st As on 30th As on 31st Rs. Cr. Rs. Cr. Sep’23 Mar’23 Sep’23 Mar’23 Shareholders Funds 364.14 339.44 Non Current Assets 263.37 249.43 Share Capital 9.20 9.20 Plant, Property & Equipment 165.00 160.98 Other Equity 354.94 330.24 Capital
Slide 11: Company Overview
S a > S= @ > oe) > E © 2. E ° re)
Slide 12: Snapshot of Company, Strategic focus, Strong Balance Sheet
Snapshot of Company Strategic focus To become Leader in Hospital Business in India with 4 Strong Balance Sheet growing divisions contributing 38% to revenue Total Debt to Equity at 0.27 in FY22-23 3 State of art manufacturing facilities in India – Rs. 1,666 Cr 1 Formulations and 2 APIs (Synthetic +
Slide 13: Strong Business Model
Strong Business Model 01 Businesswise Revenue – H1 FY23-24 Hospital API, Co. 37% Hospital Business Mkt & is major growth 03 Others driver 47% Trade 16% n 02 n Hospital Business API Business Critical Care Division API Legacy Business Businesswise Revenue – FY22-23 Intensive Care Division New
Slide 14: Vertically Integrated State of Art Manufacturing Capabilities
Vertically Integrated State of Art Manufacturing Capabilities Location Particulars Haridwar Hyderabad Vapi Artemis Biotech Themis Medicare Ltd. Themis Medicare Ltd. (Division of Themis Medicare Ltd.) Segment Formulations Synthetic APIs Synthetic APIs Tablets (Nos.) - 520 mn Ointment (No. of Tubes) -
Slide 15: Strong Research and Development Capabilities
Strong Research and Development Capabilities Continued Investment in R&D (Rs. Cr.) Business API Formulations Total Manpower 54 12 13.64 R&D 35 (Incl. 3 PhD) 6 (Incl. 2 PhD) 9.51 8.50 Analytical Lab 19 6 Development 5.28 4.59 Groups 5 3 3.43 Product in a year with 5–8 20-24 documentation FY17-18 FY18
Slide 16: Way Ahead
Way Ahead
Slide 17: Hospital Business Opportunity
n Hospital Business Opportunity Why Hospital Business Segment? Growing market - Themis has strong foot in door through Critical Care Market Highly Fragmented unlike West where 3-4 players control 90% market share Opportunities to grow segments within HB High Entry Barriers Large Product Port
Slide 18: Our Aspirations
Our Aspirations Vision & Position Provide hospitals and health systems ‘The Best Experience Leader business model” to ensure customer satisfaction Leadership in Anesthesia and Critical Care Strategy Focus on Hospital business APIs to be developed - in-house New Target Markets consumption and
Slide 19: Thank You
Thank You It takes one word to change the world “POSSIBILITY” For further information, please contact: Mr. Sangameshwar Iyer Mr. Amit Sharma / Ms. Disha Shah Tel: +91 9867726686 / 9699060134 Themis Medicare Ltd Adfactors PR Pvt Ltd Email: sangameshwar.iyer@themismedicare.com Email: amit.sharma@adfac